Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Intellia Therapeutics, Inc.
NTLA
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$17.56
▲ +1.86%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$7.95 - $28.25
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 60.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CRISPR/Cas9 technology
- Diverse therapeutic pipeline
- Strategic pharmaceutical partnerships
- Advanced genetic engineering capabilities
Bear Case
1 risk
- Above-average volatility (beta 1.8).
Growth
Revenue decline expected
Expanding genetic medicine market
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+31.3% over 3m
Quality
Loss-making
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying NTLA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 30, 2026
MAY 11, 2026
Reported EPS of -$0.81 vs -$0.92 consensus (+12.0% surprise). Revenue of $15.0M vs $13.8M expected (+9.0%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+12.0%
Next: Apr 30, 2026
Revenue trend · last 8Q
—
—
+772%
-43%
+105%
+51%
+79%
-9%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$7.0M
$9.1M
$12.9M
$16.6M
$14.2M
$13.8M
$23.0M
$15.0M
Margins · last 8Q
Gross
—
Profit
-639.5%
Wall Street consensus
14 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
43%
Sell
7%
Median Price Target
$17.00
▼ -3.2% vs $17.56
Latest: HC Wainwright · Jun 15, 2026
6 analysts covering